Outlook on Super Aged Society － Perspectives on social security system reform －

Mr. Yoshihide Esaki

Deputy Director-General for Healthcare and Medical Policy,Ministry of Economy, Trade and industry Commerce and Service Policy Group, Ministry of Health, Labor and Welfare Healthcare and Medical Policy Bureau, Healthcare and Medical Policy office Cabinet Secretariat Government of Japan

In Japanese

Pharma / Biotech

Luncheon

Oct.10(Wed.)
12
:
00
~
13
:
00

F201

【L-1】
Bayer Yakuhin, Ltd.

Pre-Registration requiredFullSimultaneous interpretation

Open Innovation Strategy at Bayer

At Bayer, since the establishment of Open Innovation Center in 2014, we have been seeking partners in diverse areas of drug discovery researches quite actively in Japan. As the result, we successfully formed research alliances with multiple universities and biotech companies. Moreover, in June this year, we opened a biotech venture incubator for the first time among the foreign-affiliated companies. In this seminar, we will introduce our global open innovation strategy and our local activities focusing on CoLaborator Kobe.

Life Innovation Forum - Era of Integrated Healthcare -

Practical and sustainable system, which link clinics to advanced medicine, is needed for integrated healthcare. The application of digital technology also should be considered. In this seminar, we are introducing challenges of Europe and Japan, and are discussing what is needed for innovation.

Our intestine is inhabited by a large diverse microbiota. It is important to reveal what kind metabolites are produced by gut microorganisms and understand the health effects of the metabolites. The new analytical method of gut microbial lipid metabolites and application of newly found metabolites to health promotion will be introduced. This information expand our knowledge of the molecular basis on the mutual relationship between the host and the gut microbiota. The discussion could open a new concept ''postbiotics to benefit everybody''.

Coordinator

Prof. Jun Ogawa

ProfessorDivision of Applied Life SciencesGraduate Schools Agriculture, Kyoto University

Three challenging tasks for development of innovative nucleic acid drugs: selectivity, delivery and cost

In recent years, the development and launch of nucleic acid drugs has been thriving. In this session, we will review the current situation of development, clarify the issues, and discuss future trends of research and development of nucleic acid drugs. In particular, we will focus on selectivity (side effects), delivery and cost, which are the challenges in developing nucleic acid drugs.

Coordinator

Prof. Takeshi Wada

ProfessorFaculty of Pharmaceutical SciencesTokyo University of Science

Oligonucleotide Therapeutics : The Past and the Present

Dr. Nagata Tetsuya

Research associate professorDepartment of Neurology and Neurological Science Tokyo Medical and Dental University

In Japanese

Development of a platform technology for non-toxic oligonucleotide therapeutics

Prof. Satoshi Obika

Professor Graduate School of Pharamaceutical SciencesOsaka University

In Japanese

FROM STEREOPURITY TO PRECISION MEDICINE: OPTIMIZING THE PROPERTIES OF ANTISENSE NUCLEIC ACID THERAPEUTICS

Dr. Naoki Iwamoto

Principal ScientistDrug Discovery,Wave Life Sciences

Oligo manufacturing to assist the growth of the pipeline and the commercial products

Mr. Nobuhiko Nishio

ManagerBusiness Management Dept. Medical Div. Nitto Denko Corporation

In Japanese

Sponsor

Oct.11(Thu.)
10
:
00
~
11
:
30

F202

【S-4】
Japan Pharmaceutical Manufacturers Association

Pre-Registration requiredFull

" Toward industrial application of human microbiome research through cross-border collaboration within Asia”

Human microbiome research has been recognized as the emerging research area based on many findings suggesting significant relationship between human microbiome and human health status as well as many diseases. There are still hurdles to realize application of human microbiome data to healthcare industry mainly due to lack of reliable protocols which guarantee reproducibility of data. In addition, it is well known that the microbiome composition is significantly different in different ethnic regions. For example, composition of Japanese gut microbiome is quite unique compared to others. Therefore, promotion of industrial application of human microbiome research requires reliable databases established based upon regional and ethnic backgrounds. In this session, we will invite a key opinion leader from the Netherlands to know how they have generated reliable database from cohort studies. We will also invite some researchers from Asian countries to grasp ongoing activities on human microbiome research in their countries. In addition, an activity of JMBC, an industry consortium to promote application of microbiome research to industry, will be presented. At the panel discussion, we will exchange ideas about how to promote industrial application of human microbiome research within Asia by leveraging cross-border collaborations.

Coordinator

Dr. Jun Terauchi

Steering Committee Chair Japan Microbiome Consortium

Dr. Wei-Kang Chi

Distinguished ScientistDevelopment Center for Biotechnology, Taiwan

The Lifelines cohort study: building a 10K Metagenomics project in healthy volunteers

Forefront of biopharmaceutical manufacturing:Innovation of biologics production process by introducing AI

AI has already been introduced in various industrial fields. However, the introduction of AI into the development and manufacturing process of biopharmaceuticals was delayed in efforts not only in Japan but also globally. In the field of biopharmaceuticals, AI hardly penetrated due to several reasons, such as using unstable animal cells as production cells or producing by batch method.Recently, following low molecular drugs, continuous production methods have been discussed even in biopharmaceuticals, and technological development has been actively carried out. In this process, elemental technologies such as new manufacturing materials and equipment, development of sensors for process monitoring, process analysis technology, process automation are being developed globally. Then, by introducing AI to process management, there has been a move to construct a highly productive production process by collecting all data on the process, analyzing it comprehensively, and controlling the process.In this session, we will give lectures on relevant contents from the viewpoint of university and industry to engage in the development and manufacture of biopharmaceuticals. We will discuss how AI should be introduced in the manufacture of biopharmaceuticals, and at the same time explore why AI introduction is delayed in the development and manufacture of biopharmaceuticals in Japan.

Coordinator

Prof. Kazuhisa Uchida

ProfrssorGraduate School of Science,technology and InnovationKobe Univaersity

Overview

Prof. Kazuhisa Uchida

ProfrssorGraduate School of Science,technology and InnovationKobe Univaersity

Utilization of IT/AI technology in the production process of biologics

Prof. Michihiro Araki

ProfessorGraduate school of medicine Kyoto University

In Japanese

Automation and future applications for improvement of biopharmaceutical manufacturing through measurement, computation and control

Mr. Soichiro Shimoda

New Technology Development Center, Life Innovation Business HeadquartersYokogawa Electric Corporation

Japan and Germany are two of the world's major pharmaceutical markets, with both countries advancing to become global heavyweights in the medical biotechnology industry. Cooperation between the two can achieve potential synergy effects that allow their respective biotech and pharmaceutical economies to become more dynamic, innovative and competitive. To support the creation of a strong German-Japanese network within the pharmaceutical and biotechnology industries, the German government initiative HEALTH MADE IN GERMANY invites German and Japanese pharmaceutical and medical biotechnology representatives to attend this luncheon seminar and panel discussion.Major companies (e.g. Bayer and Boehringer Ingelheim), highly innovative German SMEs and start-ups as well as German representatives from biotech clusters and governmental agencies will be on hand to present available cooperation and partnership opportunities and discuss shared solutions. You are very welcomed to join HEALTH MADE IN GERMANY and the best in German medical biotech at this event.

Coordinator

Mr. Axel Lohse

Manager Medical Biotechnology and PharmaceuticalsHEALTH MADE IN GERMANY c/o Germany Trade and Invest

AI X Medicine: How can we integrate empirical expert knowledge into massive data flow by AI?

Recent advancement of measurement instrument and handling and analysis of massive data flow brings revolution of personalized and precision medicine. Traditionally, medicine relies of perception of health condition and accumulation of empirical knowledge. At most standard therapy based on limited test results was the limit. Now massive data acquisition, at molecular level (DNA, RNA protein and metabolite), at imaging level (pathology, various imaging technology) and behavior pattern level (food, exercise, sleep) is progressing.

How can we integrate traditional empirical knowledge by experts (i.e pathologist, radiologist, physicians, pharmacist) into AI based technologies? In this session we will discuss about past, present and future of AI ( Dr, Okanohara), AI driven cell sorting (Dr. Ohta), AI based cancer treatment (Dr, Nishimura) and drug development based onintegration of multi-omics data (Dr. Han). All presentators will be young and top level active scientist from various field and countries.

Coordinator

Dr. Tatsuhiko Kodama

Cancer-Metabolism Project Leader Research Center for Advanced Science and Technology The University of Tokyo

Head of Computational BiologyMilner Therapeutics InstituteUniversity of Cambridge

Panel discussion

Sponsor

Oct.11(Thu.)
13
:
30
~
15
:
30

F202

【S-7】
Flanders Investment & Trade

Pre-Registration requiredSimultaneous interpretation

The 19th Belgium-Flanders Life Sciences Seminar -The life sciences eco-system in Belgium-Flanders and collaboration opportunities-

Decades of advanced knowhow, academically-trained and entrepreneurial people, and continuous innovation: these are the main ingredients that have made Flanders, the northern region of Belgium, a world leader in life sciences. More than 200 life sciences companies are working closely with universities, research institutes and hospitals. They form a mature and unique life sciences cluster in the heart of Europe. Leading organizations/companies from Flanders will participate in this seminar and demonstrate how various organizations/companies are operating a world-class research infrastructure and how they interact in a successful and efficient way to create the present strength of Belgium-Flanders in biotechnology and life sciences.

In this seminar experts including Professor Kunio Ito (Hitotsubashi University) will introduce the essence of "Ito Review 2.0: Biomedical Edition" and environmental issues on fundraising by listed biotechs. With regard to listed biotechs, a global comparison and strategies for post-IPO growth will be focused in the panel discussion.

Coordinator

Prof. Kunio Ito

ProfessorGraduate School of Business Administration Hitotsubashi University

The Background and Key Points of "Ito Review 2.0:Biomedical Edition"

Prof. Kunio Ito

ProfessorGraduate School of Business Administration Hitotsubashi University

Digital Transformation in Pharma/Healthcare

The trend of Digital Transformation due to the innovation of the digital health has created new technologies, industries and social concepts. It is also changing the business model of the conventional pharmaceutical industry. In this session, we will introduce the business model of new players participating in digital health, and discuss how the pharmaceutical industry and medical / healthcare industry should change.Keyword: Platform business

【S-15】
The National Institute of Advanced Industrial Science and Technology (AIST)

Pre-Registration requiredFull

“Front line of the Microbiome Researches” - Drug discovery, agriculture and environment –

Microorganisms show various functions, through interacting with human, animals, plants, and microbes themselves. While it is hard to culture most microbes, AIST has developed various kinds of analytical techniques, and promotes the microbiome study for many aspects. AIST pushes forward precision management technology development and the standardization of the microbiome measurement, and supports your microbiome research and developments. Furthermore, we will introduce recent our research, for example, elucidation of the variety and function of symbiosis microbes of pests, excavation of the new functions including the recovery of energy and resources from liquid wastes, through analyses of the variety and genome information of the microbes.

Coordinator

Dr. Masanori Gotoh

Innovation CoordinatorDepartment of Life Science and Biotechnology National Institute of Advanced Industrial Science and Technology (AIST)

Improving the reliability and comparability of microbiome measurements

Dr. Yuji Sekiguchi

Principal Research ManagerBiomedical Research Institute, AIST

In Japanese

Pest management by controling gut microbiota

Dr. Yoshitomo Kikuchi

Senior ResearcherBioproduction Research Institute, AIST

In Japanese

Deciphering the wastewater sludge microbiome

Dr. Takashi Narihiro

Senior ResearcherBioproduction Research Institute, AIST

In Japanese

Sponsor

Oct.12(Fri.)
13
:
30
~
15
:
00

F205-206

【S-16】
Life Innovation Area Conference

Pre-Registration required

Keihin Coastal Area Life Innovation Special Zone Seminar ～The Way to creating an Innovative Ecosystem in the Keihin Coastal Area～

The Keihin Coastal Area hosts global companies and together they aspire to develop innovative medicines, medical equipment, and to create a health and life-science industry. This seminar's theme is "The Way to creating an Innovative Ecosystem in the Keihin Coastal Area". We welcome 3 important leaders from this special zone who work in fields such as venture and incubator driving innovation, and they will talk about the future vision of this leading area in view of the Japanese economy.

Coordinator

Mr. Mitsuru Miyata

CEOMiyata Institute of Technologies

Mr. Kenichi Harada

Incubation and Investment Manager KSP,Inc. (Kanagawa Science Park)

In Japanese

Mr. Akihiko Nagata

Director CFO, euglena Co.,Ltd. / CEO, Real Teck Fund

In Japanese

Dr. Kiyofumi Kaneshiro

Executive Vice PresidentPeptiDream Inc.

In Japanese

Panel Discussion

Coordinator and Panelists

In Japanese

Sponsor

Oct.12(Fri.)
14
:
45
~
16
:
45

F202

【S-18】
Japan Agency for Medical Research and Development

Pre-Registration required

The First Success Story (Medical Technology) of Medical Research and Development Programs Focused on Technology Transfer: Acceleration Transformative Research for Medical Innovation (ACT-M/MS)

Current of Cancer Genomic Medicine

Social implementation of the cancer genomic medicine based on genome sequence analysis is an urgent issue in Japan. In this session, we introduce preceding overseas efforts and survey the role of the companies in effective cancer genomic medicine.

Coordinator

Prof. Satoru Miyano

ProfessorHuman Genome Center, Institute of Medical Science University of Tokyo

The Future Health System

Trends in Digital Transformation due to digital health innovation have created not only new technologies and industries, but also the concept of well-being beyond traditional medical. In this session, we introduce the initiatives of Global Digital Health Partnerships, Digital Health Society, and data health advances such as Australia, Northern Europe, Southern Europe, etc. from the viewpoint of data health. We will also discuss changes that the Digital Health Society brings.

Coordinator

Prof. Hiroaki Miyata

ProfessorDepartment of Health Policy and ManagementSchool of Medicine,Keio Univercity

Introduction

Prof. Hiroaki Miyata

ProfessorDepartment of Health Policy and ManagementSchool of Medicine,Keio Univercity

Challenges to Digital Health Society in Japan

Ms. MARI YAMAMOTO

Councillor for the MinisterMinister's Secretariat Ministry of Health,Labour and Welfare

The 9th Canada Life Sciences Seminar ＠BioJapan2018Investment and Business Opportunities in Regenerative Medicine - Canadian Landscape and Success Story

Canada is one of the leaders in regenerative medicine innovation. Since the team of Drs. James Till and Ernest McCulloch discovered the stem cell in 1961, Canada has been a hotbed of ground-breaking innovations in regenerative medicine. One such example is the work of Dr. John E. Dick of Toronto University, who last year received the prestigious Keio Medical Science Prize for his research on cancer stem cells. Canada's support of a wide range of research and development and commercialization of research in regenerative medicine through investment at the federal and provincial levels combined with various tax incentives and the availability of highly educated talent, makes Canada an attractive destinations for your business and investment. This seminar will provide an overview of regenerative medicine reserach, development and commercialization in Canada. The seminar will feature the Vice President of the National Research Council (NRC), who will discuss the landscape of regenerative medicine research and introduce NRC programs supporting research and commercialization. The seminar will also feature a Canadian start-up company, Aspect Biosystems that develops bio-printing technology to address challenges in regenerative medicine.

Opening Remarks: Overview of Canada's Biotech Industry

Mr. Andrew Casey

President and CEOBIOTECanada

Regenerative Medicine Landscape in Canada

Dr. Roman Szumski

Vice-President (Life Sciences)National Research Council of Canada (NRC)

Enabling the Creation of Human Tissues on Demand through Strategic Partner Engagement and Ecosystem Development - Aspect Biosystems Inc.

Mr. Tamer Mohamed

President and CEOAspect Biosystems Inc.

Organizer

Oct.10(Wed.)
15
:
00
~
16
:
30

F205-206

【O-3】
Latest approaches by Japanese companies in regenerative medicine

Latest approaches by Japanese companies in regenerative medicine

Latest approaches for regenerative medicine will be presented by the representatives of Japanese companies.

Coordinator

Mr. Hidenori Kanno

Chair, Steering CommitteeForum for innovative Regenerative Medicine

Research and Development of Implant-type Regenerated Cartilage(Regenerative Medeicine Products)Utilizing Auto-auricular Tissue Derived Chondrocytes and its Application to Cleft Lip-nose Deformity Treatment for Patients with Cleft Lip And Palate

Administrative activities on promoting the industrialization of regenerative medicine

Representatives from administrative ministries and organization introduce their activities on promoting the industrialization and perspectives. The session presents lectures, followed by panel discussion.

DirectorDivision of Regenerative Medicine Research, Department of Research Promotion Japan Agency for Medical Research and Development

In Japanese

Panel discussion

Sponsor

Oct.11(Thu.)
13
:
15
~
14
:
45

F205-206

【S-6】
TAKARA BIO INC.

Pre-Registration requiredFull

Commercialization and related issues on development of regenerative medicine, cell and gene therapy products

In the context of regenerative medicine / gene therapy products, the development of which is accelerated in Japan, in this seminar we will have talk by leading experts, focusing on fundamental research of iPS cells and gene therapy getting closer to practical use. In addition, we introduce Takara Bio's technologies relating to gene therapy and our CDMO business.

Introduction

Dr. Junichi Mineno

Managing Director, President of Bioindustry Business UnitTakara Bio Inc.

Update in iPS Cell Research

We will illustrate the progress in iPS cell Research, especially focusing on clinical studies with allo iPS cell Stock in Japan, and will discuss on the problems and solutions to bring iPS cell derived tissues or cells to paitients.

Coordinator

Prof. Mitsuru Miyata

CEOMiyata Institute of Technologies

Recent Progress in iPS Cell Research and Application

Prof. Shinya Yamanaka

Director/Professor Center for iPS Cell Research and Application (CiRA), Kyoto University

In Japanese

Development of iPS derived Cardiac Cell Sheet

Prof. Yoshiki Sawa

Professor and ChairmanDepartment of Cardiovascular Surgery Osaka University Graduate School of Medicine

The cell and gene therapy market has experienced an immense growth driven by recent landmark approvals and commercial launches. While these products are showing remarkable therapeutic efficacy, there is an emerging need for manufacturing platforms and solutions to allow for production at scale to meet market demand globally, reduce costs resulting in commercially viable therapies and achieve consistent product of highest quality and safety. Lonza will outline the specific challenges development and manufacturing of these groundbreaking therapies are facing and provide solutions how innovative platforms and solutions may help overcome some of the issues faced by the industry.Nikon CeLL innovation will introduce GCTP/cGMP compliant CDO/CMO facility and its services located in Tokyo, under Nikon-Lonza Partnership.

Cell and gene therapy: what’s next ....

Dr. Thomas Fellner

Head of cell and gene therapyPharma & BiotechLonza

CDMO Facility Introduction of Nikon CeLL innovation Co., Ltd.

Mr. Toshiyuki Nakayama

PresidentNikon CeLL innovation Co., Ltd.

In Japanese

Healthcare

Organizer

Oct.10(Wed.)
15
:
30
~
17
:
00

F203-204

【O-4】
global trend of healthcare innovation for super-aged society in Japan and the world ~with report of 1st Well Aging Society Summit Asia-Japan~

global trend of healthcare innovation for super-aged society in Japan and the world ~with report of 1st Well Aging Society Summit Asia-Japan~

We will present an overview of "1st Well Aging Society Summit Asia-Japan" held on October 9th the day before this seminar. We will announce global innovation that will contribute to super-aged society by reviewing the products and services from companies participated in the above summit. We will also talk about global issues on super-aged society such as dementia with experts from the world such as Japan, the US and Europe and discuss the direction of each country's efforts and problem solving by panel discussion.

Coordinator

Mr. Kazumi Nishikawa

DirectorCommerce and Service Industry Policy GroupMinistry of Economy, Trade and Industry

Healthcare industry based on scientific evidence

In the super aged society we are facing, it is required to build a society that can live healthy and active lives for a long time. For that, healthcare before getting illness is important. Particularly, it is urgent to take measures against "Frailty" which causes mental and physical weakness and "Sarcopenia" which causes a decline in activity due to a decrease in muscle mass. However, factors causing "Frailty" and "Sarcopenia" are not single, and in order to prevent them it is necessary to clarify the relationship with various factors in daily life. Various research activities and scientific approaches have been made to solve this. Lecture from these various experts, deepen the understanding of healthcare for "Frailty" and "Sarcopenia" and discuss how to scientifically do to develop healthcare business.

Coordinator

Dr. Katsunori Matsuoka

Vice-President, Director General, Department of Life Science and BiotechnologyNational Institute of Advanced Industrial Science and Technology

Prevention and management of frailty and sarcopenia in a super-aged society

Dr. Hidenori Arai

Director National Center for Geriatrics and Gerontology

In Japanese

Using linked, integrated 'big data' to assess opportunities to improve health outcomes in the frail and sarcopenic

Ms. Sara Sekelj

Data AnalystImperial College Health Partners

Frailty prevention measures of Kashiwa City

Ms. Yukiko Takagi

Assistant Director Kashiwa City Health and Welfare Department Community Comprehensive Support Division

Diets and gut microbiota in the control of health and diseases

Accumulating evidence has indicated that microbiota coexisting in humans especially gut commensal bacteria regulate the development of disease and thus we now recognized the importance of commensal bacteria in the maintenance and promotion of human health. We also know that diets play a key role in the control of our body condition. In addition to their direct interaction with host, the interaction between diets and microbiota is another importance factor. Current advances in analytical technologies allow the providing new knowledge based on scientific evidence. In this session, we will introduce the cutting-edge information and discuss the future direction on this field.

Coordinator

Dr. Jun Kunisawa

Project leader National Institutes of Biomedical Innovation, Health and Nutrition

From Kanagawa! Formulating Open Innovation Hub for Innovative Healthcare Technology-Cooperation of Tonomachi and Shonan iPark: Focusing on Regenerative Medicine-

Kanagawa Prefectural Government and Takeda Pharmaceutical Company Ltd. concluded MOU regarding cooperation in healthcare fields in April 2018, and implementing sevral projects for realizing innovative healthcare technologies. This seminar introduce Research Complex Program including Life Innovation Center in Tonomachi area and Shonan Health Innovation Park (iPark), and discuss open innovation for practical use of innovative healthcare technologies. We also present future cooperation between Tonomachi and Shonan iPark.

Coordinator

OrganizerResearch Complex Program

Activities of the Research Complex in Tonomachi towards future innovation ecosystem

Single-cell research: Advances and applications

Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo

In Japanese

SMARTer ICELL8 cx- an integrated imaging and targeted dispensing platform for your single cell analysis: See more discover more!

Dr. Prashant Wani

Takara Bio USA, Inc.

Environment / Energy

Organizer

Oct.12(Fri.)
10
:
15
~
11
:
45

Main Stage

【M-3】
Cellulose Nano-Fiber

Pre-Registration not requiredSimultaneous interpretation

Cellulose Nano-Fiber: Its characteristics and challenges as a high-functional nano-materials based on biomass

Cellulose Nano-Fiber (CNF) has the unique structure and characteristics as a new nano-material based on biomass. Currently, expected demands of CNF on multipurpose utilization for high performance and value-added products is increasing from various fields. On the other hand, variation of structure and characteristics of CNF samples derived from preparation methods should be considered toward proper adaptation in its marketing. In this seminar, the latest information on fundamental research and technical development on CNF will be presented and the challenges on application of CNF will be discussed.

Coordinator

Prof. Masahiro Samejima

ProfessorDepartment of Biomaterial Sciences, Graduate School of Agricultural and Life Sciences The University of Tokyo

Japan Bioindustry Association (JBA) celebrated the 30th anniversary of its foundation last year. Concomitantly with this anniversary, JBA evolved previous awards to newly established "Japan Bioindustry Award" and "Bioindustry Research Award". The Japan Bioindustry Award is given to an incomparable work which has contributed significantly to bioindustry's development or envisaging significant industry development in near future. The Bioindustry Research Award is given to young researchers engaged in outstanding research activities appreciating practical application potentials. Ceremony of both the Japan Bioindustry Award and the Bioindustry Research Award will be held with award lecture by the winner of Japan Bioindustry Award. There will also be poster presentations by ten winners of the Bioindustry Research Award.

【Japan Bioindustry Award Winner】Development of biologics for asthma based on discovery of IL-5/IL-5 receptor

Prof. Kiyoshi Takatsu

DirectorToyama Prefectural Institute for Pharmaceutical Research

In Japanese

【Bioindustry Research Award Winner】Establishment of new functional lipids based on lipid metabolism analysis of intestinal bacteria

Mr. Shigenobu Kishino

Associate ProfessorGraduate School of AgricultureKyoto University

In Japanese

【Bioindustry Research Award Winner】Gut-initiated control of immunological environment as a new era of healthcare science

Managing Director, Honjo International / Chairperson of the Council for Fostering Medical Ventures

In Japanese

Axcelead Drug Discovery Partners, Inc.

In Japanese

Johnson&Johnson Innovation

In Japanese

Nippon Boehringer Ingelheim Co.,Ltd.

In Japanese

Health2.0 Director-Japan

In Japanese

Luncheon

Oct.11(Thu.)
11
:
30
~
13
:
00

F205-206

【L-3】
Shonan Health Innovation Park

Pre-Registration requiredFullSimultaneous interpretation

Creating a stage that all innovators can aim the world-Shonan iPark's challenge-iPark will externally present its medium term strategy for the first time. A world leading industrial cluster organizer from Boston, US, will provide the latest information on open innovation. Through lectures and discussions, iPark aims to externally communicate methods in which it could help to create a groundbreaking innovation ecosystem in Japan.

Coordinator

Prof. Shinya Sakuma

Project ProfessorGraduate School of Media and GovernanceKeio University

Creating a stage that all innovators can aim the world-Shonan iPark's challenge-

Bio-cluster Summit 2018 - Global Health Data Sharing

Many countries are emphasizing biocluster policies. We will discuss together about the specific issues of biocluster policies among people concerned with bio-related policies of representative bioclusters of Japan, USA, the various countries of Europe, and Asian countries. We expect them towards international knowledge exchange among bioclusters in the world. This year we will discuss international health data sharing

Support for SMEs and Venture Business of Life Science Sector through Venture Fund(Introduction of Global Alliance Scheme)

Introduction of "Axil Life Science & Healthcare Fund" that specializes in biomedical & healthcare technology investments, with emphasis on supporting the growth of early stage ventures. They aims to find new seeds from academia and to support global development of its business through collaboration with the international companies.

SMRJ and JETRO also will explain the support scheme of "Global Alliance" that push such kind of effort for promoting investment to Japan.

For commercialization and effective social implementation of products developed through genome editing, 1) science-based and transparent regulations, 2) IP environment which encourages more players entering to the field, and 3) sound and unique ideas which connect genomic information to diverse consumer values are indispensable. Regulatory considerations and IP discussion are in progress globally. Therefore, looking into the future, ideas on how to make the most advantage of genome editing techniques not in the area of agriculture but also in pharmaceuticals and industrial products would become crucial for business. In this session, we first review the environment surrounding commercialization of genome-edited products in the world, especially in EU. Then, we will discuss opportunities and possibilities that the genome editing techniques bring to our future by introducing ideas and efforts in connecting genomic information with products which provide values to various stakeholders.

Coordinator

Dr. Mieko Kasai

ProfessorCenter for Environment, Health and Field SciencesChiba University